Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

Szczegóły
Abstrakt

Tytuł:: Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Autorzy:: Umezawa Y; Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX, 77030, USA. .
Źródło:: International journal of hematology [Int J Hematol] 2023 Jan; Vol. 117 (1), pp. 24-29. Date of Electronic Publication: 2022 Sep 10.
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Publication: 2008- : Tokyo : Springer Japan
Original Publication: Amsterdam : Elsevier Science Publishers, c1991-
MeSH Terms:: Tyrosine Kinase Inhibitors*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy
Humans ; Protein Kinase Inhibitors/adverse effects ; Molecular Targeted Therapy
References:: Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–3. (PMID: 10.1038/243290a0)
Morita K, Sasaki K. Current status and novel strategy of CML. Int J Hematol. 2021;113:624–31. (PMID: 10.1007/s12185-021-03127-5)
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–27. (PMID: 10.1056/NEJMoa1609324)
Jain P, Kantarjian H, Alattar ML, Jabbour E, Sasaki K, Gonzalez GN, et al. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. Lancet Haematol. 2015;2:e118–28. (PMID: 10.1016/S2352-3026(15)00021-6)
Sasaki K, Strom SS, O’Brien S, Jabbour E, Ravandi F, Konopleva M, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2:e186–93. (PMID: 10.1016/S2352-3026(15)00048-4)
Jain P, Kantarjian H, Sasaki K, Jabbour E, Dasarathula J, Nogueras Gonzalez G, et al. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. Br J Haematol. 2016;173:114–26. (PMID: 10.1111/bjh.13936)
Sasaki K, Kantarjian HM, Jain P, Jabbour EJ, Ravandi F, Konopleva M, et al. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 2016;122:238–48. (PMID: 10.1002/cncr.29745)
Haddad FG, Sasaki K, Issa GC, Garcia-Manero G, Ravandi F, Kadia T, et al. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol. 2022. https://doi.org/10.1182/blood-2021-154380 . (PMID: 10.1182/blood-2021-154380)
Sasaki K, Kantarjian HM, O’Brien S, Ravandi F, Konopleva M, Borthakur G, et al. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol. 2019;109:545–52. (PMID: 10.1007/s12185-019-02620-2)
Sasaki K, Lahoti A, Jabbour E, Jain P, Pierce S, Borthakur G, et al. Clinical safety and efficacy of nilotinib or dasatinib in patients with newly diagnosed chronic-phase chronic myelogenous leukemia and pre-existing liver and/or renal dysfunction. Clin Lymphoma, Myeloma Leuk. 2016;16:152–62. (PMID: 10.1016/j.clml.2015.12.003)
Jain P, Kantarjian H, Boddu PC, Nogueras-González GM, Verstovsek S, Garcia-Manero G, et al. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019;3:851–61. (PMID: 10.1182/bloodadvances.2018025874)
Takaku T. Management of vascular adverse events during tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Rinsho Ketsueki. 2020;61:1018–27.
Sakaida E. What is the best treatment for chronic-phase CML? Rinsho Ketsueki. 2021;62:1012–23.
Iurlo A, Cattaneo D, Bucelli C, Breccia M. Dose optimization of tyrosine kinase inhibitors in chronic myeloid leukemia: a new therapeutic challenge. J Clin Med. 2021;10:1–12. (PMID: 10.3390/jcm10030515)
Réa D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138:2031–41. (PMID: 10.1182/blood.2020009984)
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84. (PMID: 10.1038/s41375-020-0776-2)
Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35:440–53. (PMID: 10.1038/s41375-020-01111-2)
Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, et al. Final 5-year study results of DASISION: the Dasatinib versus imatinib study in treatment-Naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333–40. (PMID: 10.1200/JCO.2015.64.8899)
Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36:231–7. (PMID: 10.1200/JCO.2017.74.7162)
Cortes JE, Kim DW, Kantarjian HM, Brümmendorf TH, Dyagil I, Griskevicius L, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30:3486–92. (PMID: 10.1200/JCO.2011.38.7522)
Cortes JE, Kim D-W, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783–96. (PMID: 10.1056/NEJMoa1306494)
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393–404. (PMID: 10.1182/blood-2016-09-739086)
Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47. (PMID: 10.1161/01.CIR.97.18.1837)
Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Verschuren M, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J. 2012;33:1635–701. (PMID: 10.1093/eurheartj/ehs092)
Rea D, Mirault T, Raffoux E, Boissel N, Andreoli AL, Rousselot P, et al. Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia. Leukemia. 2015;29:1206–9. (PMID: 10.1038/leu.2014.342)
Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33:4210–8. (PMID: 10.1200/JCO.2015.62.4718)
Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, Talpaz M, et al. Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016;48:84–91. (PMID: 10.1016/j.leukres.2016.07.007)
Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138:2042–50. (PMID: 10.1182/blood.2021012082)
Kantarjian HM, Deininger MW, Abruzzese E, Apperley J, Cortes JE, Chuah C, et al. Efficacy and safety of ponatinib (PON) in patients with chronic-phase chronic myeloid leukemia (CP-CML) who failed one or more second-generation (2G) tyrosine kinase inhibitors (TKIs): analyses based on PACE and optic [Abstract]. Blood. 2020;136(43–4):Abstract 647.
Deininger MW, Apperley JF, Arthur CK, Chuah C, Hochhaus A, De Lavallade H, et al. Post hoc analysis of responses to ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) by baseline BCR-ABL1 level and baseline mutation status in the optic trial [abstract]. Blood. 2021;138:307. (PMID: 10.1182/blood-2021-145995)
Cortes JE, Hochhaus A, Kantarjian HM, Guilhot F, Kota VK, Hughes TP, et al. Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION [abstract]. J Clin Oncol. 2017;35(15_suppl):7051. (PMID: 10.1200/JCO.2017.35.15_suppl.7051)
Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, et al. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020;126:67–75. (PMID: 10.1002/cncr.32504)
Murai K, Ureshino H, Kumagai T, Tanaka H, Nishiwaki K, Wakita S, et al. Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2021;8:e902–11. (PMID: 10.1016/S2352-3026(21)00333-1)
Hughes TP, Munhoz E, Aurelio Salvino M, Ong TC, Elhaddad A, Shortt J, et al. Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd. Br J Haematol. 2017;179:219–28. (PMID: 10.1111/bjh.14829)
Hochhaus A, Rosti G, Cross NCP, Steegmann JL, Le Coutre P, Ossenkoppele G, et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia. 2016;30:57–64. (PMID: 10.1038/leu.2015.270)
Castagnetti F, Gugliotta G, Bocchia M, Trawinska MM, Capodanno I, Bonifacio M, et al. Dose optimization in elderly CML patients treated with bosutinib after intolerance or failure of first-line tyrosine kinase inhibitors. Blood. 2019;134:496–496. (PMID: 10.1182/blood-2019-127514)
Crugnola M, Castagnetti F, Breccia M, Ferrero D, Trawinska MM, Abruzzese E, et al. Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. Ann Hematol. 2019;98:2329–38. (PMID: 10.1007/s00277-019-03767-y)
Latagliata R, Breccia M, Carmosino I, Cannella L, De Cuia R, Diverio D, et al. “Real-life” results of front-line treatment with Imatinib in older patients (≥65 years) with newly diagnosed chronic myelogenous leukemia. Leuk Res. 2010;34:1472–5. (PMID: 10.1016/j.leukres.2010.07.001)
Aitken MJL, Benton CB, Issa GC, Sasaki K, Yilmaz M, Short NJ. Two cases of possible familial chronic myeloid leukemia in a family with extensive history of cancer. Acta Haematol. 2021;144:585–90. (PMID: 10.1159/000513925)
Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Shamanna RK, et al. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 2016;127:1269–75. (PMID: 10.1182/blood-2015-10-674242)
Morita K, Kantarjian HM, Sasaki K, Issa GC, Jain N, Konopleva M, et al. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer. 2021;127:2641–7. (PMID: 10.1002/cncr.33539)
Morita K, Jabbour E, Ravandi F, Borthakur G, Khoury JD, Hu S, et al. Clinical outcomes of patients with chronic myeloid leukemia with concurrent core binding factor rearrangement and Philadelphia chromosome. Clin Lymphoma Myeloma Leuk. 2021;21:338–44. (PMID: 10.1016/j.clml.2020.12.025)
Saxena K, Jabbour E, Issa G, Sasaki K, Ravandi F, Maiti A, et al. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol. 2021;14:1–10. (PMID: 10.1186/s13045-021-01106-1)
Maiti A, Franquiz MJ, Ravandi F, Cortes JE, Jabbour EJ, Sasaki K, et al. Venetoclax and BCR-ABL tyrosine kinase inhibitor combinations: outcome in patients with Philadelphia chromosome-positive advanced myeloid leukemias. Acta Haematol. 2020;143:567–73. (PMID: 10.1159/000506346)
Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients. Cancer. 2017;123:4391–402. (PMID: 10.1002/cncr.30864)
Sasaki K, Kantarjian H, O’Brien S, Ravandi F, Konopleva M, Borthakur G, et al. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer. 2018;124:1160–8. (PMID: 10.1002/cncr.31187)
Haddad F, Kantarjian H, Issa GC, Jabbour E, Sasaki K. Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia. Leuk Lymphoma. 2022;1:1–4.
Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, et al. Clonal chromosomal abnormalities appearing in Philadelphia chromosome–negative metaphases during CML treatment. Blood. 2017;130:2084–91. (PMID: 10.1182/blood-2017-07-792143)
Shoukier M, Borthakur G, Jabbour E, Ravandi F, Garcia-Manero G, Kadia T, et al. The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. Haematologica. 2021;106:2853–8. (PMID: 10.3324/haematol.2020.260125)
Sasaki K, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Wierda WG, et al. The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: a model to improve patient outcomes. Am J Hematol. 2021;96:241–50. (PMID: 10.1002/ajh.26047)
Alfayez M, Richard-Carpentier G, Jabbour E, Vishnu P, Naqvi K, Sasaki K, et al. Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia. Br J Haematol. 2019;187:543–5. (PMID: 10.1111/bjh.16245)
Contributed Indexing:: Keywords: CML; Dose optimization; Tyrosine kinase inhibitor
Substance Nomenclature:: 0 (Tyrosine Kinase Inhibitors)
0 (Protein Kinase Inhibitors)
Entry Date(s):: Date Created: 20220910 Date Completed: 20230106 Latest Revision: 20231213
Update Code:: 20240104
DOI:: 10.1007/s12185-022-03431-8
PMID:: 36087226
: Czasopismo naukowe

Full Text Finder

The therapeutic outcomes of chronic myeloid leukemia (CML) have improved dramatically since tyrosine kinase inhibitors (TKIs) became available in clinical practice. Life expectancy of patients with CML is now close to that of the general population. Patients with CML who achieve sustained deep molecular response may discontinue TKI therapy. However, most patients still require TKI therapy for long periods without sustained deep molecular response. Given the awareness of increased incidence of arterial occlusive events in patients on TKI therapy, the optimal TKI selection should be based on age, comorbidities, risk classification, and goals of treatment. Dose optimization of TKI therapy reduces the incidence of adverse events while maintaining efficacy in CML.
(© 2022. Japanese Society of Hematology.)

Informacja